Clinical trial
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
NCT02963090
Study timeline
Study start (actual)2017-05-20Date precision: day
Registry last updated2023-02-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small Cell Lung Cancerunresolved
Interventions
TopotecanDRUG · verified · RxNorm: topotecan
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Alliance Foundation Trials, LLC.lead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02963090 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.